The Fine Print Nobody Reads Until It's Too Late: A Founder's Clause-by-Clause Term Sheet Autopsy

You got the term sheet. You screenshotted the valuation, texted your co-founder, maybe cracked a beer. Then you forwarded the whole thing to a startup attorney and waited for the green light.

Here's the problem: a lot of lawyers — especially generalist ones doing you a favor at a friend's rate — will scan for the big stuff (valuation, liquidation preference, board seats) and let the rest slide. And the rest is where first-time founders get quietly wrecked two years later at Series A.

Let's do the autopsy your sign-off meeting probably wasn't.

The Clause Risk Ranking Nobody Gives You

Not all term sheet clauses are created equal. Some are boilerplate. Some are landmines. Here's how they stack up for a seed-stage founder:

Red flags — fight these:

Redemption rights. This one's been crawling back into seed docs lately, and it's genuinely dangerous. It lets investors force the company to buy back their shares after a set window (often 5–7 years) if there's been no exit. Sounds dormant, right? It's not. If your company is alive but not exit-ready, investors can demand a cash payout you don't have, and in some constructions, that obligation sits on the cap table like a debt. If redemption rights show up in a seed term sheet, that's a negotiation trigger, not a formality.

Participating preferred. The classic double-dip. Investors get their money back first, then share in the upside. At seed stage with a modest round, it's survivable — but it compounds. If you sign participating preferred at seed and the next investor wants the same, your exit math gets ugly fast. Non-participating (1x) should be your baseline ask.

Drag-along with a low threshold. Drag-along itself is fine — it prevents one holdout shareholder from killing an acquisition everyone else wants. The question is who can trigger it and at what vote. If 50% of preferred can force all common shareholders (that's you, founder, with your vesting stock) to sell, you've handed over your exit veto. Push for a higher threshold and carve-outs for founders.

Yellow flags — understand before you sign:

Pay-to-play. Requires investors to buy their pro-rata in future rounds or lose protective provisions (sometimes get converted to common). Sounds founder-friendly — it punishes VCs who won't support you. And honestly, at seed it often is. The catch: sophisticated investors may read it as a sign you've been advised by someone adversarial, and some top-tier firms just won't sign it. Know what you're trading.

Information rights. Barely anyone reads these, and they're usually harmless — quarterly financials, annual budget. The risk is scope creep: overly broad info rights mean more investors with a legal right to your sensitive data, which complicates future diligence and can spook later-stage firms worried about confidential leakage. Cap the number of information-right holders if you can.

Anti-dilution weighted average vs. full ratchet. Full ratchet is nearly extinct in seed docs, but if you see it, kill it. Weighted average is standard and fine.

Green flags — standard, stop stressing:

• Pro-rata rights (normal, though watch how many investors hold them)
• No-shop provisions (standard 30–45 day exclusivity — just know your clock)
• Standard vesting requirements

Why Your Lawyer Might Miss This

Startup counsel isn't a monolith. A $2,500 flat-fee review from a generalist is a different product than a $15,000 negotiation from a firm that closes venture deals weekly. Neither is wrong — but you need to know which one you bought.

The generalist reads for legal risk. The venture specialist reads for downstream risk: how this document plays at Series A, what signals it sends to institutional investors, which clauses have become red flags on diligence checklists since the 2022 repricing. Your Series A investor's counsel will read your seed docs with a magnifying glass. Someone should read them with the same intensity on your side first.

Five Questions to Ask Your Startup Counsel

Founders ask "Is this standard?" and stop there. Ask these instead:

1. "Which clauses in here would a Series A investor's counsel flag during diligence?" This reframes the review from legal compliance to market signaling.

2. "What have you seen change in seed terms in the last 18 months?" Terms cycle. Redemption rights were nearly dead in 2020; they're back in 2024-25 deal flow. A lawyer who hasn't priced a seed deal since the ZIRP era is working from stale instincts.

3. "If I signed this as-is, what specifically would cost me at the next round — in dollars or control?" Force the hypothetical. Make them walk the forward scenario, not just flag grammar.

4. "What would you push back on if this were your company, and what's not worth the fight?" A good lawyer tells you where to spend negotiating capital. A great one tells you where the investor will walk.

5. "Who exactly is doing this review — you or an associate?" Not rude. Necessary. The person whose name is on the engagement letter should be the person who's read your cap table.

The Real Cost of a Bad Signature

Term sheets aren't binding — everyone knows that. But the financing documents they preview are, and by the time you're reading the actual stock purchase agreement, the negotiation window has largely closed. The term sheet is your one moment of leverage where walking away is cheap.

A drag-along at 50%, a redemption right with a five-year fuse, participating preferred stacked on future rounds — none of these hurt you the day you sign. They hurt you on the day you're selling the company, or raising a bridge, or explaining your cap table to a Series A partner who just quietly knocked a million off your valuation.

The valuation on page one is the number everyone celebrates. The clauses on pages four through nine are the ones that determine what you actually keep. Read both. Then make your lawyer read them out loud.